Apogee Therapeutics (APGE) Preferred Stock Liabilities (2022 - 2023)
Apogee Therapeutics' (APGE) quarterly Preferred Stock Liabilities came in at $148.5 million in Q3 2023, up 1717.35% year-on-year from $8.2 million in Q3 2022, and up 412.57% on a QoQ basis from $29.0 million in Q2 2023.
Apogee Therapeutics (APGE) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Apogee Therapeutics (APGE) has 2 years of Preferred Stock Liabilities data on file, last reported at $148.5 million in Q3 2023.
- On a quarterly basis, Preferred Stock Liabilities rose 1717.35% year-over-year to $148.5 million in Q3 2023; TTM through Sep 2023 was $148.5 million, a 1717.35% increase from a year earlier, with the FY2022 full-year figure at $29.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2023 stood at $148.5 million, up from $29.0 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for APGE reached as high as $148.5 million in Q1 2023 and fell as low as $3.8 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Apogee Therapeutics | 9.35 Bn | 8.29 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 148.50 Mn |
| Jun 30, 2023 | 28.97 Mn |
| Mar 31, 2023 | 148.50 Mn |
| Dec 31, 2022 | 28.97 Mn |
| Sep 30, 2022 | 8.17 Mn |
| Jun 30, 2022 | 3.77 Mn |